Шаблоны LeoTheme для Joomla.
GavickPro Joomla шаблоны

Short Communication

Radiotherapy and Rosai-Dorfman Disease

Antonio Cássio Assis Pellizzon1*, MD, Ph.D., Ricardo Cesar Fogaroli1, MD, Maria Leticia Gobo Silva1, MD, Michael
Jenwei Chen1, MD, Guilherme Gondim1, MD, Douglas de Castro Guedes1, MD, Henderson Ramos1, MD

1AC Camargo Cancer Center, Sao Paulo, Brazil

*Corresponding author: Dr. Antonio Cássio Assis Pellizzon, Rua Prof Antonio Prudente, 211, Liberdade, São Paulo, Brazil – 01509-020, Fax: +55-11-21895101; Email: acapellizzon@accamargo.org.br

Submitted06-27-2016 Accepted:  08-26-2016 Published: 09-01-2016

Download PDF

_________________________________________________________________________________________________________________________

 

Article

Abstract

Rosai–Dorfman disease (RDD) also known as histiocytosis with lymphadenopathy is uncommon, often self-limiting benign, not– Langerhans-cell histiocytic proliferative disorder. It usually affects young adults and children, with no predilection for sex. More than 80% of patients present with painless cervical lymphadenopathy, with or without fever. Other presentation sites include upper aero-digestive tract, orbits, and the paranasal sinuses. Extra nodal involvement can occur from 20% to more than 40% of cases, and common sites of involvement include the skin, upper airway, soft tissue, bones kidney, lower respiratory tract, liver, orbit and central nervous system. Treatment is not necessary for most instances, but some patients, when symptomatic, may require medical intervention. There is no established guideline for the management of this condition and various therapeutic modalities are used, including surgery, radiotherapy and or chemotherapy.

Keywords: Proliferative Disorder; Radiotherapy; Surgery

Introduction

Rosai–Dorfman disease (RDD) is an uncommon, often self-limiting benign, not–Langerhans-cell histiocytic proliferative disorder, first described by Rosai and Dorfman in 1969 as sinus histiocytosis with lymphadenopathy [1,2]. This rare benign histiocyte disorder can have nodal and extranodal manifestations, with no concordance in the literature in this form of presentation, being the last one described from up to 20% to more than 40% of patients, in special elderly. The diagnosis is based on the cytologic and clinical findings [1-4].

Treatment is not necessary for most instances [5], but some patients, when symptomatic, may require medical intervention. In the absence of established guidelines for the management of this condition, various therapeutic modalities are used, including surgery, radiotherapy and or chemotherapy for disease manifestations [3,6].

RDD Histology

Rosai and Dorfman first described 4 cases of the clinicopathologic entity known as sinus histiocytosis with massive lymphadenopathy in 1969 [1,2].

Histological studies include RDD cells in the macrophage/histiocyte family, but their exact origin is still unknown. Scattering, clusters or sheets of large polygonal histiocytes intermingled with a florid, mixed inflammatory infiltrate. The typical pathologic displays of RDD are characterized by an attenuated infiltration of lymphoblast cells and pale histiocytes. These histiocytes are well defined, varied in size, and with round or oval vesicular nuclei, distinct nucleoli, and abundant amphophilic to eosinophilic granular or clear cytoplasm. Patch and bandlike infiltrate of numerous mature plasma cells around glands and vessels is a constant finding [7]. The presence of emperipolesis of leukocytes, which can be highlighted by S-100 protein stain, and concurrent histiocytosis on pathology examination is mandatory, histiocytes also have abundant cytoplasm [1].

A report published by Eisen et al. showed that RDD cells can also express “pan-macrophage” antigens such as EBM11, HAM 56, and Leu-M3, antigens functionally associated with phagocytosis (Fc receptor for IgG, complement receptor 3), and lysosomal activity (lysozyme, alpha 1-antichymotrypsin, and alpha 1-antitrypsyn),) antigens associated with early inflammation (Mac-387, 27E10),) antigens commonly found on monocytes, but not tissue macrophages (OKM5, Leu-M1), and “activation” antigens (Ki-1 and receptors for transferrin and interleukin 2). These data suggest that SHML cells are true functionally activated macrophages that may be recently derived from circulating monocytes [8].

RDD Presentation

RDD is a benign disorder, of unknown etiology, usually associated with lymph node enlargement in various superficial or deep sites that usually affects young adults and children, with no predilection for sex. More than 80% of patients present with painless cervical lymphadenopathy, with or without fever [1,2]. Other presentation sites include upper aero-digestive tract, orbits, and the paranasal sinuses.

Common sites of extra nodal involvement include the skin, upper airway, and soft tissue [9,10]. Bones can also be affected, but are the less frequent presentation [1,3]. Figures 1 and 2 show a CT scan of a lesion presenting in the left femur with important infiltration of periosteal reaction and muscular and soft tissue infiltration.

The lesions presenting in the skin, in general, have a xanthomatous appearance, papular or nodular, with no more than 4 cm in diameter [11]. However, lesions with the size of up to 12 cm have been reported [12].

RDD also can occur in a variety of other sites, including the genitourinary system, lower respiratory tract, oral cavity, and soft tissues [13]. Involvement of kidney, lower respiratory tract, or liver was found to be a poor prognostic sign, and patients with the associated immunologic disease often fared poorly (9).

Approximately 33% of cases present with extranodal disease and 10% have orbital involvement with only one-third of these having bilateral disease. Orbital involvement often presents as painless proptosis. Patients can present with lesions in the skin of the lids or other soft tissues of the orbit. Difficulties with extra ocular movements and lid closure can follow with the more progressive disease. Corneal ulceration, decreased visual acuity and blindness can occur eventually [14].

Involvement of the CNS remains, however, rare with 32 reported cases in the literature. All patients underwent surgical treatment and the primary pre-operative diagnosis was meningioma in 93% of the cases [15].

In general, the prognosis has been found to correlate both with the number of nodal groups and with the number of extra nodal
systems involved by RDD [9].

RDD Treatment

Currently, there are no clear guidelines and no ideal treatment protocol exists for the management of RDD. The disease may have a benign course without therapy, but surgery may be required to relieve obstructive symptoms. Table 1 shows suggested treatment options according to disease presentation.

Initial management usually consists of either incisional or excisional biopsy, followed by observation in most cases. The surgical management is usually reserved for recurrent lesions causing functional disability or obstruction of critical structures.

About one-third of patients can achieve a complete or partial response to the use of corticosteroids alone. In more symptomatic and advanced disease various chemotherapeutic regimens that have been tried so far. A combination of vinca alkaloids, alkylating antineoplastic agents, and or corticosteroids appear to be the most effective [5].

Treatments with acyclovir or interferon alpha have also being documented in the literature with anecdotal responses [15,16].

There is a paucity of information in the literature describing techniques and doses of radiation therapy (RT), despite its relative
success, and probably due to its relationship with potential malignant transformation. Advances in the planning and delivery of RT in its various modalities warrant the reporting of recent RT treatments.

The largest series reporting the use of RT in the treatment of RDD was published by Komp et al [5]. RT treatments were documented in 34 out of 418 patients with RDD. Unfortunately, RT dose was reported in only 18 patients, with no clear relationship between dose and response. There were 5 patients who received doses between 30 Gy and 49 Gy, with 1 patient presenting complete response and another partial response, and 3 had no response. Doses above 50 Gy were used in 2 patients, achieving a partial response in 1 and no response in the second. The remaining 11 patients received doses of less than 30 Gy, with 3 partial and 8 absence of response.

Modern RT techniques, such as intensity-modulated radiation therapy (IMRT), have been introduced to minimize the risk of treatment-related toxicity, but they have not been formally evaluated in this situation.

RT can also be prescribed as primary or postoperative treatment, and in some instances to treat recurrent disease.

As the etiology of the heterogenic response rates of these tumors is still unclear, we conclude that due the paucity of data and published papers mainly based on case reports or small cohorts, an RT dose–response relationship cannot currently be securely suggested. Other factors that affect the definition of this relationship are poor reporting of treatment plans and dosimetry, a variation on schedule and dose fractionation of radiotherapy, besides the rarity of the disease, patient inconvenience, in general, daily treatments over 2 weeks, expense and somewhat obscure mechanisms of action.

radio table 32.1

Table 1. Suggested treatment options according to the presentation.

References

References

  1. Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy. A newly recognized benign clinicopathological entity. Arch Pathol. 1969, 87(1): 63-70.
  2. Rosai J, Dorfman RF. Sinus histiocytosis with massive lymphadenopathy: a pseudo lymphomatous benign disorder. Analysis of 34 cases.Cancer. 1972, 30(5):1174-1188.
  3. Annessi G, Giannetti A. Purely cutaneous Rosai--Dorfman disease. Br J Dermatol. 1996, 134(4):749-753.
  4. Rodriguez-Galindo C, Helton KJ, Sánchez ND, Rieman M, Jeng M et al. Extranodal Rosai-Dorfman diseases in children. J Pediatr Hematol Oncol. 2004, 26(1): 19-24.
  5. Komp DM. The treatment of sinus histiocytosis with massive lymphadenopathy (Rosai-Dorfman disease). Semin Diagn Pathol. 1990, 7(1): 83-86.
  6. Saboo SS, Jagannathan JP, Krajewski KM, O'Regan K, Hornick JL et al. Symptomatic extranodal Rosai-Dorfman disease treated with steroids, radiation, and surgery. J Clin Oncol. 2011, 29(31): e772-775.
  7. Thawerani H, Sanchez RL, Rosai J, Dorfman RF. The cutaneous manifestations of sinus histiocytosis with massive lymphadenopathy. Arch Dermatol. 1978,114(2): 191-197.
  8. Eisen RN, Buckley PJ, Rosai J. Immunophenotypic characterization of sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease). Semin Diagn Pathol 1990, 7(1): 74–82.
  9. Kong YY, Kong JC, Shi DR, Lu HF, Zhu XZ et al. Cutaneous rosai-dorfman disease: a clinical and histopathologic study of 25 cases in China. Am J Surg Pathol. 2007, 31(3): 341-350.
  10. Foucar E, Rosai J, Dorfman R. Sinus histiocytosis with massive lymphadenopathy (Rosai–Dorfman disease), review of the entity. Semin Diagn Pathol. 1990,7: 19–73.
  11. Hsiao CH, Tsai TF, Yang TH, Liu CM. Clinicopathologic characteristics of Rosai-Dorfman disease in a medical center in northern Taiwan. J Formos Med Assoc. 2006, 105(9): 701-707.
  12. Thawerani H, Sanchez RL, Rosai J, Dorfman RF. The cutaneous manifestations of sinus histiocytosis with massive lymphadenopathy. Arch Dermatol. 1978, 114(2): 191-197.
  13. Young PM, Kransdorf MJ, Temple HT, Mousavi F, Robinson PG. Rosai-Dorfman disease presenting as multiple soft tissue masses. Skeletal Radiol. 2005, 34(10): 665-669.
  14. Childs HA 3rd, Kim RY. Radiation response of Rosai-Dorfman disease presenting with involvement of the orbits. Am J Clin Oncol. 1999, 22(5): 526-528.
  15. Petzold A, Thom M, Powell M, Plant GT. Relapsing intracranial Rosai-Dorfman disease. J Neurol Neurosurg Psychiatry. 2001, 71(4): 538-541.

Cite this article: Antonio Cássio Assis Pellizzon. Radiotherapy and Rosai-Dorfman Disease. J J Rad Oncol. 2016, 3(3): 032.

Contact Us:
9600 GREAT HILLS
TRAIL # 150 W
AUSTIN, TEXAS
78759 ( TRAVIS COUNTY)
E-mail : info@jacobspublishers.com
Phone : 512-400-0398